Scientists look to genetics to explain why GLP-1 drugs work for some people but not for others People taking popular new ...

People taking popular new weight-loss drugs such as Wegovy and Zepbound often celebrate the number of pounds they shed and ...

The obesity rate for adults in the U.S. dropped to 37% in 2025 after peaking at 39.9% in 2022, but diabetes has reached an ...

An analysis found that a shrinking waist size was responsible for only around a third of the cardiovascular benefits in ...

Novo Nordisk (NVO) recruits top healthcare analyst Michael Novod, a long time bull of the company, as head of its investor ...

This article was reviewed by Darragh O’Carroll, MD. Long-Term Side Effects of Wegovy® Key takeaways: The long-term side ...

As obesity drug heavyweights Eli Lilly and Novo Nordisk gear up to release results for the third quarter, investors are ...

It might sound shocking to read about such drastic actions, but it’s stories of overweight children being bullied and too ...

Amy Schumer revealed that she had tried medications like Ozempic and Wegovy before switching to Mounjaro, which she said ...

Somehow, it’s becoming even harder to get a GLP-1.

Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded ...